Effect of a disintegration mechanism on wetting, water absorption, and disintegration time of orodispersible tablets

Journal of Young Pharmacists

Volumn 4, Issue 3, 2012, Pages 157-163

  Pabari, R M ^a   Ramtoola, Z ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Absorption ratio; disintegration time; orodispersible tablets; porosity; wetting time

Indexed keywords

CROSPOVIDONE; GLYCOLIC ACID; SODIUM;

ABSORPTION RATIO; ANALYSIS OF VARIANCE; ARTICLE; DISINTEGRATION TIME; DRUG ABSORPTION; ORODISPERSIBLE TABLET; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET FRIABILITY; TABLET POROSITY; TENSILE STRENGTH; WETTING TIME;

EID: 84866654758     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.100021     Document Type: Article

References (28)

1. Bhoyar P, Biyani D, Umekar M. Formulation and characterization of patient-friendly dosage form of ondansetron hydrochloride. J Young Pharm 2010;2:240-6.
2. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004;21:433-76.
3. Sandri G, Bonferoni MC, Ferrari F, Rossi S, Caramella C. Differentiating factors between oral fast-dissolving technologies. Am J Drug Deliv 2006;4:249-62.
4. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82.
5. Klancke J. Dissolution testing of orally disintegrating tablets (CIMA LABS INC, Brooklyn Park, MN). Dissolut Technol 2003;10:6-9.
6. McLaughlin R, Banbury S, Crowley K. Orally disintegrating tablets the effect of recent FDA guidance on ODT technologies and applications pharmaceutical technology the industry's authoritative source 2009.
7. Makino T, Yamada M, Kikuta J. Fast dissolving tablet and its production. US Patent 5720974: Takeda Chemical Industries Ltd, Osaka Japan 1998.
8. Amborn J, Tiger V. Apparatus for handling and packaging friable tablets. US Patent 6311462 Cima Labs, Inc. (Eden Prairie, MN); 2001.
9. Wehling F, Schuehle S, Madamala N. Effervescent dosage form with microparticles. US Patent 5,178,878; 1993.
10. Remya K, Beena P, Bijesh P, Sheeba A. Formulation development, evaluation and comparative study of effects of super disintegrants in cefixime oral disintegrating tablets. J Young Pharm 2010;2:234-9.
11. Battu SK, Repka MA, Majumdar S, Rao YM. Formulation and evaluation of rapidly disintegrating fenoverine tablets: Effect of superdisintegrants. Drug Dev Ind Pharm 2007;33:1225-32.
12. Fukami J, Yonemochi E, Yoshihashi Y, Terada K. Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose. Int J Pharm 2006;310:101-9.
13. Jacob S, Shirwaikar A, Nair A. Preparation and evaluation of fastdisintegrating effervescent tablets of glibenclamide. Drug Dev Ind Pharm 2009;35:321-8.
14. Late SG, Yu YY, Banga AK. Effects of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets. Int J Pharm 2009;365:4-11.
15. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull 1996;44:1361-6.
16. Shah U, Augsburger L. Multiple sources of sodium starch glycolate, NF: Evaluation of functional equivalence and development of standard performance tests. Pharm Dev Technol 2002;7:345-59.
17. Khinchi MP, Bhandari A, Sharma N, Gupta M, Agarwal D. Design and development of orally disintegrating tablets of famotidine prepared by direct compression method using different super-disintegrants. J Appl Pharm Sci 2011;1:50-8.
18. Bi Y, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm 1999;25:571-81.
19. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull 1996;44:2121-7.
20. Ramtoola Z, Pabari R, Kelly J. A Method of producing fast dissolving tablets. WO Patent WO/2008/120,181; 2008.
21. Heinz R, Wolf H, Schuchmann H, End L, Kolter K. Formulation and development of tablets based on Ludipress and scale-up from laboratory to production scale. Drug Dev Ind Pharm 2000;26:513-21.
22. Rajpurohit H, Sharma P, Sharma S, Purohit S, Bhandari A. Hordeum vulgare hull in the design of fast disintegrating tablets. J Young Pharm 2011;3:211-5.
23. Sugimoto M, Narisawa S, Matsubara K, Yoshino H, Nakano M, Handa T. Effect of formulated ingredients on rapidly disintegrating oral tablets prepared by the crystalline transition method. Chem Pharm Bull 2006;54:175-80.
24. Zhao N, Augsburger LL. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS PharmSciTech 2005;6:120-6.
25. Kornblum SS, Stoopak SB. A new tablet disintegrating agent: Cross linked polyvinylpyrrolidone. J Pharm Sci 1973;62:43-9.
26. Remya K, Beena P, Bijesh P, Sheeba A. Formulation development, evaluation and comparative study of effects of super disintegrants in cefixime oral disintegrating tablets. J Young Pharm 2010;2:234-9.
27. Abdelkader H, Abdalla OY, Salem H. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation. AAPS PharmSciTech 2007;8:156-66.
28. Sharma S, Sher P, Badve S, Pawar AP. Adsorption of meloxicam on porous calcium silicate: Characterization and tablet formulation. AAPS PharmSciTech 2005;6:618-25.